Thompson Investment Management Inc. Lowers Stock Position in GSK plc (NYSE:GSK)

Thompson Investment Management Inc. cut its position in shares of GSK plc (NYSE:GSK) by 19.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,293 shares of the pharmaceutical company’s stock after selling 553 shares during the quarter. Thompson Investment Management Inc.’s holdings in GSK were worth $78,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. SG Americas Securities LLC boosted its stake in shares of GSK by 167.3% in the 3rd quarter. SG Americas Securities LLC now owns 18,773 shares of the pharmaceutical company’s stock worth $767,000 after buying an additional 11,749 shares during the last quarter. Brookstone Capital Management boosted its position in GSK by 2.8% in the third quarter. Brookstone Capital Management now owns 26,457 shares of the pharmaceutical company’s stock worth $1,082,000 after purchasing an additional 718 shares during the last quarter. Ritholtz Wealth Management grew its stake in GSK by 2.8% in the 3rd quarter. Ritholtz Wealth Management now owns 78,540 shares of the pharmaceutical company’s stock valued at $3,211,000 after purchasing an additional 2,143 shares during the period. Gilman Hill Asset Management LLC increased its position in shares of GSK by 9.7% during the 3rd quarter. Gilman Hill Asset Management LLC now owns 67,422 shares of the pharmaceutical company’s stock valued at $2,756,000 after purchasing an additional 5,965 shares during the last quarter. Finally, Thomasville National Bank raised its stake in shares of GSK by 2.5% during the 3rd quarter. Thomasville National Bank now owns 475,384 shares of the pharmaceutical company’s stock worth $19,434,000 after purchasing an additional 11,771 shares during the period. 15.74% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and reduced their target price for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Six research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Stock Performance

NYSE GSK opened at $36.03 on Monday. The firm has a market cap of $74.68 billion, a P/E ratio of 22.66, a price-to-earnings-growth ratio of 1.42 and a beta of 0.64. The company has a quick ratio of 0.53, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The company’s 50 day moving average is $34.25 and its 200-day moving average is $37.56. GSK plc has a 12-month low of $31.72 and a 12-month high of $45.92.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Sell-side analysts predict that GSK plc will post 4.07 earnings per share for the current year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be paid a $0.3932 dividend. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 annualized dividend and a yield of 4.36%. This is an increase from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is currently 93.08%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.